Prostate Cancer
Long-term survival data in phase II trial of GVAX vaccine reported at conference
Published in Cancer Weekly, June 11th, 2002
Cell Genesys, Inc. (CEGE) has reported encouraging long-term survival data from a phase II multicenter clinical trial of GVAX prostate cancer vaccine which demonstrates a dose-dependent trend toward prolonged survival in patients with hormone-refractory prostate cancer metastatic to bone. In the 34-patient study, 7 of 10 (70%) patients receiving the higher-dose level of the vaccine are alive 2.5 years after treatment (median survival >30 months).
Of the 24 patients receiving the lower dose of the vaccine, 9 of 22 patients (41%) are alive 2.5 years after treatment (median survival 22 months), and 2 were lost to follow-up. These results compare favorably with the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2002-06-11)
More Articles from Cancer Weekly
- Oncogenes
Suppressing MDM2 gene reduces tumor mass in soft tissue sarcoma - Thalidomide
Agent an active cancer fighter in patients with relapsed multiple myeloma - Chemotherapy
Freezing cancer cells makes them prime targets for anticancer drug, new study finds - Colon Cancer
Researchers uncover biochemical connection to high-fat diets - Colorectal Cancer
Encapsulated vaccine more effective than vaccine suspensions for reducing tumor burden - Pathology
Alcohol may hasten the progression of cancer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
